Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 475-479

  Harnack, Ulf ^a   Johnen, Heiko ^a   Pecher, Gabriele ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CD86; Cytotoxicity; Interleukin 2; Myeloma; YT

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL DENSITY; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MYELOMA CELL; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER LIKE CELL LINE YT; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION;

ANTIGENS, CD80; ANTIGENS, CD86; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, NATURAL; MULTIPLE MYELOMA;

EID: 79953248411     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK and Durie B: Survival and years of life lost in different age cohorts of patients with multiple myeloma J Clin Oncol 28: 1599-1605, 2010.
2. Richardson PG, Weiler E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossmann RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Raster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL and Anderson KC: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-686, 2010.
3. Palumbo A and Rajkumar SV: Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Eur J Haematol 84: 379-390, 2010.
4. Frohn C, Höppner M, Schlenke P, Kirchner H, Koritke P and Luhm J: Anti-myeloma activity of natural killer lymphocytes. Brit J Haematol 119: 660-664, 2002. (Pubitemid 35366205)
5. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, Groh V, Spies T, Pollio G, Cosman D, Catalano L,Tassone P, Rotoli B and Venuta S: HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258, 2005.
6. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleornado V, Cippitelli M, Fionda C, Petrucci MT, Guarini A, Foà R and Santoni A: ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype. Blood 113: 3503-3511, 2009.
7. Klingemann HG and Martinson J: Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6: 15-22, 2004.
8. Brandenburg S, Takahashi T, de la Rosa M, Janke M, Karsten G, Muzzulini T, Orinska Z, Bulfone-Paus S and Scheffold A: IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T-cells. Eur J Immunol 38: 1643-1653, 2008.
9. Lundqvist A, Yokoyama H, Smith A, Berg M and Chields R: Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 113: 6120-6127, 2009.
10. + T-regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582-1587, 2006.
11. Tam YK, Martinson JA, Doligosa K and Klingemann HG: Ex vivo expansion of the highly cytotoxic human natural killer-92 cell line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5: 259-272, 2003.
12. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J and Klingemann H: Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10: 625-632, 2008.
13. Suck G, Branch DR and Keating A: Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol 82: 355-361, 2006. (Pubitemid 43932713)
14. Schirrmann T and Pecher G: Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer. Cancer Immunol Immunother 50: 549-556, 2001. (Pubitemid 34028288)
15. Schirrmann T and Pecher G: Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 9: 390-398, 2002. (Pubitemid 34289458)
16. Yodoi J, Teshigawara K, Nikaido T, Fukui K, Noma T, Honjo T, Takigawa M, Sasaki M, Minato N, Tsudo M, Uchiyama T and Maeda M: TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol 134: 1623-1630, 1985.
17. Yoneda N, Tatsumi E, Kawano S, Teshigawara K, Oka T, Fukuda M and Yamaguchi N: Detection of Epstein-Barr virus genome in natural killer-like cell line YT. Leukemia 6: 136-141, 1992.
18. Azuma M, Cayabyab M, Buck D, Phillips JH and Lanier LL: Involvement of CD28 in MHC-unrestricted cytotoxicity mediated by a human natural killer leukemia cell line. J Immunol 149: 1115-1123, 1992.
19. Teng JM, Liu XR, Mills GB and Dupont B: CD28-mediated cytotoxicity by the human leukemia NK cell line YT involves tyrosine phosporylation, activation of phosphatidylinositol-3-kinase, and protein kinase C. J Immunol 156: 3222-3232, 1996. (Pubitemid 26123536)
20. Brown RD, Pope B, Yuen E, Gibson J and Joshua DE: The expression of T-cell-related co-stimulatory molecules in multiple myeloma. Leuk Lymphoma 31: 379-384, 1998. (Pubitemid 29033959)
21. Pope B, Brown RD, Gibson J, Yuen E and Joshua D: B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 96: 1274-1279, 2000. (Pubitemid 30658455)
22. Yamashita T, Tamura H, Satoh C, Shinya E, Takahashi H, Chen L, Kondo A, Tsuji T, Dan K and Ogata K: Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clin Cancer Res 15: 770-777, 2009.
23. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M and Pellat-Deceunynck C: The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 91: 1234-1240, 2006.
24. Chiorini JA, Wendtner CM, Urcelay E, Safer B, Hallek M and Kotin RM: High-efficiency transfer of the T-cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Human Gene Ther 6: 1531-1541, 1995. (Pubitemid 26014565)
25. Drexler HG, Dirks WG and MacLeod RA: False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. (Pubitemid 29465623)
26. Pellet-Deceunynk C, Amiot M, Bataille R, van Riet I, van Camp B, Omede P and Boccadoro M: Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995.
27. DeBlaker-Hohe DF, Yamauchi A, Yu CR, Horvath-Arcidiacono JA and Bloom ET: IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells. Cell Immunol 165: 33-43, 1995.
28. Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J Jr. and Burns LJ: Low-dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biol Blood Marrow Transplant 3: 34-44, 1997. (Pubitemid 127531527)
29. Alileche A, Goldman CK and Waldmann TA: Differential effects of IL-2 and IL-15 on expression of IL-2 receptor alpha. Biochem Biophys Res Commun 285: 1302-1308, 2001. (Pubitemid 32912925)
30. Nagashima S, Mailliard R, Kashii J, Reichert TE, Herbermann RB, Robbins P and Whiteside TL: Stable transduction of the interleukine-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91: 3850-3861, 1998. (Pubitemid 28225754)
31. Bachanova V, McKenna D, Curtsinger J, Panoskaltsis-Mortari A, Lindgren BR, Cooley S, Weisdorf D and Miller JS: Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother 59: 1739-1744, 2010.
32. Siegler U, Meyer-Monard S, Jörger S, Stern M, Tichelli A, Gratwohl A, Wodnar-Filipowicz A and Kalberer CP: Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 12: 750-763, 2010.
33. + regulatory T-cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int Immunol 19: 785-799, 2007. (Pubitemid 47073268)
34. Assier E, Jullien V, Lefort J, Moreau JL, Di Santo JP, BB Vargaftig, JR Lapa e Silva and J Thèze: NK cells and polymorphonuclear neutrophils are both critical for IL-2 induced pulmonary vascular leak syndrome. J Immunol 172: 7661-7668, 2004. (Pubitemid 38747632)
35. Montel AH, Bochan MR, Goebel WS and Brahmi Z: Fas-mediated cytotoxicity remains intact in perforin and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 165: 312-317, 1995.
36. Yu J, Heller G, Chewning J, Kim S, Yokohama WM and Hsu KC: Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol 179: 5977-5989, 2007.
37. Tarazona R, Borrego F, Galiani MD, Aguado E, Pena J, Coligan JE and Solana R: Inhibition of CD28-mediated natural cytotoxicity by KIR2DL2 does not requie p56Ick in the NK cell line YT-Indy. Molecular Immunology 38: 495-503, 2001. (Pubitemid 34031838)
38. Bari R, Bell T, Leung WH, Vong QP, Chan WK, Das Gupta N, Holladay M, Rooney B and Leung W: Significant functional heterogeneity among K1R2DL1 alleles and a pivotal role of arginine 245. Blood 114: 5182-5190, 2009.